Soybeans: USDA reduced their July estimate for 2023/24 U.S. ending stocks to 300 million bushels, 50 million lower than last month. The U.S. season-average soybean price for 2023/24 is forecast at $12.40 per bushel, up $0.30 from last month. The soybean meal price is projected at $375.00 per short ton, up $10.00. The soybean oil price forecast of 60.0 cents per pound is up 2 cents. Global soybean ending stocks are reduced 2.4 million tons to 121 million - mainly on lower U.S. stocks. ...
Illuminating the value of technical research
On behalf of a commodity producer organization, WPI evaluated the outputs from a project that featured a $5 million investment into technical research over multiple years. WPI’s team captured the results of this extensive effort and synthesized them for presentation to the organization’s governing board; among the findings uncovered and presented for the first time was the development of genomic traits proven, via rigorous testing, to provide crop yield advantages of 50 percent or more to U.S. farmers in times of drought. Capturing measurable results from long-term efforts can be challenging. Educating clients on the dynamics of success measurement when quantifiable results are not readily available requires deep client-consultant collaboration and an ability to consider both near- and long-term client aspirations with market/policy dynamics – attributes that WPI brings to every consulting engagement.
The Senate Agriculture Committee will take up the farm bill next week, and a number of amendments targeting the meat industry are expected to be offered. Two of the most potentially damaging are the Schumer amendment, based on his bill, the Family Grocery and Farmer Relief Act, and mandatory co...
Oliver Goldsmith's The Deserted Village, published in 1770, is of a timeless quality. It is a 425-line lament for a disappearing rural world, where prosperous villages give way to larger estates, fewer farmers, and emigration. One passage even follows those leaving for the new colony of Georgia...
The industry has spent two years bracing for GLP-1 medications to hollow out demand, but the data so far tells a more interesting story. Roughly one in eight adults currently uses a GLP-1, and an additional 29 percent of non-users say they would consider it if it became more accessible and cost...